<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146197</url>
  </required_header>
  <id_info>
    <org_study_id>P071242</org_study_id>
    <nct_id>NCT01146197</nct_id>
  </id_info>
  <brief_title>Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics</brief_title>
  <acronym>GITAB</acronym>
  <official_title>Evaluation of Safety and Efficacity of Indometacin and Two Potassium Sparing Diuretics in Adult Patients Affected by Gitelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gitelman syndrome is a rare renal disease where the kidneys are unable to normally retain
      some salts (sodium, potassium and magnesium). Main consequences of these renal leaks of salts
      are a tendency toward low blood pressure, hypokalemia and hypomagnesemia both contributing to
      cardiac and muscles symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with received in random order 75mg/day indometacin (Chronoindocid®), 10-20 mg/day
      amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment
      will be followed by six weeks washout period. 3-6 weeks before the first period of treatment,
      a supplementation with potassium and magnesium will be orally given, and maintained at the
      same dose throughout the study and stoped 6 weeks after the end of the third period of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of indomethacin on hypokalemia versus potassium and magnesium supplementation alone</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of indomethacin on disorders possibly induced by chronic hypokalemia and /or hypomagnesemia (EKG, lipid disorders related to insulin resistance, glucose/ insulin ratio)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of eplerenone and amiloride on hypokalemia.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare indomethacin, eplerenone or amiloride in terms of efficiency on biological and hormonal disorders</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate and compare indomethacin, eplerenone or amiloride in terms of efficiency on biological and hormonal disorders other than hypokalemia (hypomagnesemia, hyperaldosteronism), glomerular filtration rate, hypotension, clinical tolerance, and quality of life.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Gitelman Syndrome</condition>
  <arm_group>
    <arm_group_label>Amiloride, Indometacin, Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiloride, indometacin(+Omeprazole), Eplerenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiloride, Eplerenone, indometacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiloride, Eplerenone, indometacin (+Omeprazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone, Amiloride, indometacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone, Amiloride, indometacin (+Omeprazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone, Indometacin, Amiloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone, Indometacin, Amiloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indometacin, Eplerenone, Amiloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indometacin, Eplerenone, Amiloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indometacin, Amiloride, Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indometacin, Amiloride, Eplerenone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TREATMENT</intervention_name>
    <description>Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.</description>
    <arm_group_label>Amiloride, Indometacin, Eplerenone</arm_group_label>
    <arm_group_label>Amiloride, Eplerenone, indometacin</arm_group_label>
    <arm_group_label>Eplerenone, Amiloride, indometacin</arm_group_label>
    <arm_group_label>Eplerenone, Indometacin, Amiloride</arm_group_label>
    <arm_group_label>Indometacin, Eplerenone, Amiloride</arm_group_label>
    <arm_group_label>Indometacin, Amiloride, Eplerenone</arm_group_label>
    <other_name>MODAMINE; Inspra and CHRONOINDOCID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 18-60 yrs old, both sex, with genetically proven Gitelman's syndrome, under
             birth pill control for woman.

        Exclusion Criteria:

          -  counter-indication to treatment under study

          -  Other diuretic or NAIS treatments than amiloride, spironolactone, or indometacin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blanchard Anne, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypokalemia</keyword>
  <keyword>Hypomagnesemia</keyword>
  <keyword>Salt loosing nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Gitelman Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Sodium Channel Blockers</mesh_term>
    <mesh_term>Diuretics, Potassium Sparing</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

